Research Article

Molecular Imaging to Predict Response to Targeted Therapies in Renal Cell Carcinoma

Table 1

Mean values ± standard deviations of (s−1) evaluated at 1 h for the four groups at both baseline (day 0, D0) and 4 days after treatment initiation (day 4, D4).

(s−1)
D0D4

Control15.3 ± 5.223.1 ± 5.1
Sunitinib15.4 ± 6.723.0 ± 13.8
Everolimus14.3 ± 5.67.9 ± 4.8
Bevacizumab16.6 ± 6.313.6 ± 8.9